Acumen Pharmaceuticals

Sehr gute News !!   Stron Buy!

Positive Daten in Phase-1-Studie zu ACU193 zur Behandlung der Alzheimer-Krankheit im Frühstadium

Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease

Acumen Pharmaceuticals, Inc.
Mon, July 17, 2023 at 1:00 PM GMT+2·3 min read
In this article:

ABOS
+56.05%
Watchlist

   Patternyahoo plus badge
   Bullish
   trade type L

Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc.

Company to host conference call and webcast for investors and analysts today, July 17, at 8 a.m. ET

CHARLOTTESVILLE, Va. and CARMEL, Ind., July 17, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will hold a conference call today to discuss the positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AβO targeting antibody therapy in early AD. To read more about the results, please see the press release here.

Conference Call Details

Acumen will host a webcast presentation and conference call for analysts and investors today, July 17, 2023, at 8:00 a.m. ET to discuss the topline data from the INTERCEPT-AD clinical trial. The webcast will feature members of Acumen’s leadership team as well as Steven DeKosky, M.D., Deputy Director of the McKnight Brain Institute at the University of Florida and member of Acumen’s scientific advisory board, and Lawrence Honig, M.D., Ph.D., Director of the New York State Center of Excellence for Alzheimer's Disease at Columbia University and an INTERCEPT-AD trial investigator.

To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN.

The webcast audio will be available via this link.

Irgendwas scheint den Marktteilnehmern an dem Phase1 Update nicht zu gefallen
investors.acumenpharm.com/news-releases/...er-phase-1-updates